Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's t…
Biotechnology
US, San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Nurix Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -2.010 | - | 14 | - | -109 | - | -13 | - | -13 | - | 10 |
| 2021 | -2.7600 | -2.543 | 17 | 35 | -43 | -98 | -62 | -93 | -131 | -98 | 16 | 26 |
| 2022 | -2.7300 | 0.585 | 29 | 47 | -117 | -226 | -111 | -209 | -123 | -227 | 31 | 35 |
| 2023 | -3.4200 | -2.336 | 38 | 94 | -166 | -143 | -173 | -237 | -194 | -256 | 37 | 57 |
| 2024 | -2.6500 | -2.814 | 76 | 54 | -143 | -153 | -141 | -50 | -344 | -51 | 42 | 41 |
| 2025 | - | -2.793 | - | 56 | - | -144 | - | -52 | - | -53 | - | 42 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |